News & events

Cannabis-based medicine to be tested in Alzheimer's trial

Researchers from the NIHR Maudsley BRC are to lead a pioneering new study into a cannabis-based treatment for people living with dementia. Alzheimer’s Research UK has awarded over £250,000 for the landmark phase II clinical trial of Sativex®, a cannabis-based medicine licenced in the UK. The drug has already been found to be safe in people and has been approved for use in the treatment of muscle stiffness and tightness experienced by people with multiple sclerosis. However, Sativex® is not currently licensed in the UK for any other indication, including treatment of the symptoms of dementia.

 

By NIHR Maudsley BRC at 21 Feb 2019

NIHR Maudsley BRC researchers host dementia discussion in collaboration with South London Theatre

Several of our researchers led an exploration of sensitive issues raised by a production of Florian Zeller’s The Father, at South London Theatre in West Norwood on Wednesday 6 February. The Q&A session was chaired by the BRC’s Engagement and Impact Fellow, Dr Sally Marlow, and featured Rob Stewart, Professor of Psychiatric Epidemiology and Clinical Informatics, who also leads the BRC’s Informatics cluster.

By NIHR Maudsley BRC at 11 Feb 2019